Inve India ▾

Medicamen Organics share price & results

Medicamen Organics Ltd· Healthcare

Results to
Mar 2026
Latest analysed call
Q4 FY25
Ownership as of
Jun 2026

Haridwar-based generic pharma contract manufacturer of tablets, capsules, liquids, ointments and dry powders, exporting to Africa and CIS via third-party distributors and a Nepal/Africa subsidiary network.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue4.6 ₹ crore−77.5% YoYQuarterly, as filedQuarter to Mar 2026Revenue from operations as filed.
Operating margin-132.0 %−145.7 pts YoYOperating profit / revenueQuarter to Mar 2026For the quarter; a change is in percentage points.
Net profit-5.0 ₹ crore−383.0% YoYQuarterly, as filedQuarter to Mar 2026Profit after tax as filed.
Return on equityUnavailable−31.5 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM · period unavailableNot in the analysed materials. No older figure is substituted.
Free cash flow margin-29.10 %−10.8 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)Unavailable−94.1 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM · period unavailableNot in the analysed materials. No older figure is substituted.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Mar 2026

Guidance

What management said, and what became of it

9 targets tracked, none judged yet · 9 open · verdicts reflect calls analysed to Q4 FY25.

Medicamen Organics Ltd management guidance track record on Inve: 9 targets tracked across analysed earnings calls (0 achieved, 0 missed, 9 open).

TargetOriginal wordingSaidLatest callVerdict
RevenueINR60 crores to INR65 crores for FY '26
Call transcript, Q4 FY25 · 4 Jun 2025		Q4 FY25Q4 FY25:Target set for FY26
Call transcript, Q4 FY25 · 4 Jun 2025		New

Source: Inve Guidance Tracker for Medicamen Organics Ltd · to Q4 FY25

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

9 of Medicamen Organics Ltd's 9 targets are still open. See which are on track and which have gone quiet. The 1 above are the free sample; 8 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹25.25 +4.99% · +₹1.2

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance −27.9% 1Y

₹20.0₹25.0₹30.0₹35.0Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26

1Y: ₹35 on 24 Oct 2025 → ₹25.25. High ₹37.9 (28 Oct 2025), low ₹19.4 (12 Jun 2026).

Previous close
₹24.05
Market cap
₹37 Cr
52-week range
₹19.4 – ₹37.9
One year
−31.20%
Return on equity (FY ending Mar 2026)
-13.66%

Overview

Symbol
NSE:MEDIORG
Exchange
NSE
Currency
INR

What Medicamen Organics Ltd does

Based on the company's own presentations, annual report and earnings calls.

Medicamen Organics develops, manufactures and distributes generic pharmaceutical dosage forms - tablets, capsules, oral liquids, ointments/gels, syrups, suspensions and dry powders - largely as a contract/third-party manufacturer for government and private institutions. It sells to private pharma companies in India and international markets (Africa, CIS, South-East Asia) through third-party distributors or on loan-license basis. Manufacturing is carried out at two WHO-GMP certified facilities in Haridwar, Uttarakhand. The company is expanding via subsidiaries into direct international distribution (Rwanda, Nepal) and has entered cosmetics/personal care under its own LOIRE brand.

Segments

  • Pharmaceutical formulations
  • Cosmetics & personal care
  • International distribution subsidiaries
Manufacturing facilities
2 WHO-GMP approved units, SIDCUL, Haridwar, Uttarakhand
Installed tablet capacity
21,600 lakh tablets/yr (Unit I 10,800 + Unit II 10,800 lakh tablets)
Installed capsule capacity
780 lakh capsules/yr (Unit II)
Installed suspension capacity
936,000 litres/yr (Unit II)
Installed ointment capacity
93,600 kg/yr (Unit II)
Installed dry-powder sachet capacity
3,744,000 sachets/yr (Unit II)
Founded 1995Headquarters New Delhi, IndiaEmployees 114 (FY25) Company website

Your own record

Start an Inve Case for Medicamen Organics Ltd

Free account: one company. Everything above stays public.

Write why you follow Medicamen Organics Ltd and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Medicamen Organics Ltd

Guides on how to read this kind of business and the numbers that matter.